Liquid biopsy when MEAT is not the treat

K Govind Babu

doi:10.4103/ijmpo.ijmpo_41_19

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 5-6
DOI: 10.4103/ijmpo.ijmpo_41_19

Editorial Commentary

Liquid biopsy when MEAT is not the treat

Authors

K Govind Babu

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Consultant, HCG Hospitals, Bengaluru, Karnataka, India

Abstract

Full Text

References

References
1 NCI at the NIH, NCI Dictionary of Cancer Terms; 2018.
2 Cristofanilli M, Budd GT, Ellis MJ, Sago H, Stopeck A, Matera J, Miller MC. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91
3 Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-21
4 de BonoJS, Scher HT, Montgomery RB, Parker C, Miller MC, Tissing H. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9
5 Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G. et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; 18: 5701-10
6 Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K. et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012; 7: 115-21
7 Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M. et al. Association Between Plasma Genotyping and Outcomes of Treatment WithOsimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J ClinOncol 2016; 34: 3375-82
8 Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J. et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 2016; 6: 209-13
9 Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D. et al. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clin Cancer Res 2016; 22: 5772-82
10 Andrél F, Ciruelos EM, Rubovszky G, Campone G, Loibl S, Rugo HS. et al.Alpelisib (ALP) + Fulvestrant (FUL) for Advanced Breast Cancer (ABC): Results of the Phase 3 SOLAR-1 Trial. Presented at: 2018 ESMO Congress. Abstract LBA3. Munich, Germany; 19-23, October 2018
11 American Cancer Society. Available from: www.cancer.org. [Last accessed on 2018 Feb 12].